Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States

Objectives To estimate annual US-level costs attributable to conjunctivitis events in patients aged 12 years with moderate-to-severe AD receiving biologic therapy To simulate potential cost savings associated with an increase in the use of tralokinumab versus other biologics based on its comparatively lower incidence of conjunctivitis events Table 1 Targeted literature inputs a Pooled estimates were obtained by applying estimated proportions of adults versus adolescents in the US to generate a weighted average.b The incidence rate of conjunctivitis among patients with moderate-severe AD was proxied by the observed incidence rate in the placebo arm of the most recent clinical trial for a biologic of interest for the treatment of moderate-to-severe AD. c The lower bound estimate for excess cost per conjunctivitis episode was obtained by applying proportions of incident allergic versus infectious conjunctivitis to separate cost estimates for allergic and infectious conjunctivitis, to generate a weighted average.